Replies to post #14861 on RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

gfp, I don't see things as hopeless as you make them out to be. Say the RD data is good. OK, Cortex licenses out CX717 for RD and gains time to test the new AMPAKINES.

Then say again the data is good for the new low and high impacts through Phase I and IIa testing. Remember, the low impacts may be effectual in the treatment of ADHD. And remember also, if the high impacts are proven safe and efficacious in increasing BDNF, Cortex may be sitting on a goal mine here. So Cortex as an entity obviously then has considerable value. And if the company really has nothing much left to do after licensing these compounds out, wouldn't a buyout be the logical endgame then?

Then there's the scenario Jerry related to us. Maybe Cortex merges with a small to mid-cap company with money in its hands, but whose compounds have already been licensed out. This buys Cortex the time it needs perhaps. Or, at some point in time, some BP likes what it sees in Cortex and simply acquires Cortex to add new promising drugs to their pipelines.

Roger Stoll's no fool. I'm sure he'll do the best he can for the company and its shareholders depending on what value Cortex proves to have when we see the results of the upcoming clinical trials.

[asuhowe]

gfp,
Anyone that thinks COR will exist as a stand alone company is nuts.. Prognosticating scenarios where COR survives based on royalties or upfronts is moot.

COR's plan is clear and simple..
1)Prove they have something that can make someone with deep pockets some serious cash.
2)Sell the company somewhere in the $3-5 range

Anyone that thinks COR is a long-term stand-alone bet is insane. They won't be the next CEPH, Amgen, etc.
They are merely making themselves attractive to a buy-out..

Look, I'm the first one on this board to admit I don't know squat about CNS technology.. However, I have seen hundreds of situations like COR in the high-tech arena .. This stock is exactly like the tech stocks that got bought out by CSCO/IBM/INTC/MSFT and the like..

What we have to focus on is not the long-term soluability of COR, but if they can put on enough make-up and wear a short enough skirt to get bought out sometime towards the end of the year...

Also, like I posted previously, buying in the .50 range is fairly safe.. Even if RD is a bust, a fire sale will still net at least .75-1.00... The next danger point for entering this stock is if things start to look promising for RD and some other new compounds, and a bit of hype begins to take us in the low $1s... That is a dangerous place to buy/hold prior to any "real" news..

So, please stop the dreaming of COR as a success and hitting $5 and beyond (not you personally gfp).. This stock is merely a buy-out target, and if you think Stoll is working hard for anything else, you're nuts..

[jerrydylan]

There is alot more money out there than that- You do not see the dire implications throughout BP. You have been mentated into a permanent bear, until it rallies enormously.

[enemem]

I think your estimate of what the RD upfront would be is low. Although the focus of the study in question is for an acute indication, it is not lost on anyone that if ampakines rescue breathing in the acute indication, they are good candidates to mitigate the risk of opiate-induced RD in the context of chronic pain management. This is a much bigger market.

Although the regulatory hurdles facing ampakines in a chronic indication are different from those in an acute indication, I nonetheless think that for companies in the lucrative opioid analgesia market, ampakines would be of considerable interest, particularly in the absence of analgesia-sparing alternatives. Because there is more than one company in this market, they will be bidding against each other.

I have no idea at all what is going to happen to COR over the next year. It is worth noting though that when this board reaches a consensus based on echo rather than news, the consensus is reliably wrong.